Krka entered the Polish market in 1974. Its overall high quality has earned the company recognition within the Polish medical community.
In the 1980s, Krka strengthened its position on the Polish market both as a company and as a brand despite the unfavorable economic situation; in 1991, it established its own representative office in Warsaw. The systematic development of operations in Poland and the gradual increase in sales and market share led to the establishment of its own enterprise. In the spring of 1993, Krka registered KRKA-POLSKA Sp. z o.o. as a 100% shareholder.
To strengthen its position in Poland and to adapt to local needs quicker, Krka built a production and distribution center. In 1997, it laid a cornerstone in Warsaw for the construction of the new complex. As part of the national competition, the Warsaw factory received the “Construction of the Year 2000” title in the category of “Industrial and administrative buildings”. Today, it remains one of the most modern pharmaceutical production facilities in Poland, consisting of high-bay and pharmaceutical warehouses, distribution and production facilities, a quality control laboratory with state-of-the-art equipment and an administration building.
Thus, Krka became a pharmaceutical wholesaler in the Polish market. For nearly 20 years it has been skillfully cooperating with scientific institutions, academic centers, ministries, clinics, doctors and pharmacists on the basis of understanding, trust and firm partnerships.
Today KRKA-POLSKA Sp. z o.o. is the 5th largest generic company out of over 300 pharmaceutical companies in Poland. It is a major domestic manufacturer of medicines and one of the most dynamic companies in the pharmaceutical sector in Poland. It also exports products to over 30 markets, including Great Britain, Germany, France, Spain and the Scandinavian countries.
Krka adapts all production conditions to meet the requirements of Good Manufacturing Practice (GMP), European and world standards, provisions in technical regulations and Polish legislation. We manufacture solid dosage forms (tablets and capsules), producing around 400 million tablets per year.
Almost 85% of the total sales of Krka’s products in Poland come from prescription medicines. The leading products in Poland are cardiovascular medicines, medicines for treating the gastrointestinal tract, central nervous system, pain relief medicines and various antibiotics. Krka also covers other therapeutic areas like diabetes, allergies, oncology, urology, medicines for certain neurological diseases, antivirals and other medicines.
KRKA also offers an attractive portfolio of over-the-counter products such as Septolete ultra, Bilobil, Nolpaza control, Nalgesin Mini and Herbion, which are popular brands in Poland. Furthermore,Polish breeders and veterinarianshave been using Krka’s veterinary products (e.g. Fypryst and Ecocid S.) for many years.
Our greatest asset is our highly specialized employees. KRKA-POLSKA Sp. z o.o. currently employs over 700 people. Working at Krka provides an interesting international environment and the possibility of continual personal and professional development. Together with employees and our external business partners we build a culture of mutual trust, respect, cooperation and teamwork.